XML 41 R31.htm IDEA: XBRL DOCUMENT v3.25.2
ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - $ / shares
3 Months Ended
May 05, 2025
Jan. 19, 2021
Jun. 30, 2025
Mar. 31, 2025
Jan. 20, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share par value     $ 0.0001 $ 0.0001  
Description of reverse stock split Company effectuated a 1 for 14 reverse stock split (the “Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on May 5, 2025. There was no change to the number of authorized shares of the Company’s common stock. All share and per share information in these financial statements are adjusted to reflect the Reverse Split.        
Series C Convertible Preferred Stock [Member] | Preferred Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued in connection with Phytanix Bio purchase, shares     5,705    
Series C-1 Convertible Preferred Stock [Member] | Preferred Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued in connection with Phytanix Bio purchase, shares     950,000    
Series D Convertible Preferred Stock [Member] | Preferred Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued in connection with Phytanix Bio purchase, shares     20,000    
Stock Purchase Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued in connection with Phytanix Bio purchase, shares     117,690    
Share par value     $ 0.0001    
Warrants to purchase common stock     715,493    
Stock Purchase Agreement [Member] | Series C Convertible Preferred Stock [Member] | Preferred Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued in connection with Phytanix Bio purchase, shares     5,705    
Share par value     $ 0.000001    
Stock Purchase Agreement [Member] | Series C-1 Convertible Preferred Stock [Member] | Preferred Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued in connection with Phytanix Bio purchase, shares     950,000    
Share par value     $ 0.000001    
Stock Purchase Agreement [Member] | Series D Convertible Preferred Stock [Member] | Preferred Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares issued in connection with Phytanix Bio purchase, shares     20,000    
Share par value     $ 0.000001    
Stock Purchase Agreement [Member] | Phytanix Bio [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share acquired         100.00%
Stock Purchase Agreement [Member] | Phytanix Bio [Member] | Series A Convertible Preferred Shares [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share acquired         100.00%
Stock Purchase Agreement [Member] | Alterola and Emc 2 [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share acquired         100.00%
Stock Purchase Agreement [Member] | ABTI Pharma [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Exchange of share   600,000,000